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Neurobiology of Disease
PSD-95 Is Essential for Hallucinogen and Atypical
Antipsychotic Drug Actions at Serotonin Receptors
Atheir I. Abbas,1* Prem N. Yadav,2*Wei-Dong Yao,7,8,9,10Margaret I. Arbuckle,11 Seth G. N. Grant,11,12Marc G. Caron,7,8,9
and Bryan L. Roth1,2,3,4,5,6
1Department of Biochemistry, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, Departments of 2Pharmacology, 3Medicinal
Chemistry, and 4Psychiatry, 5Lineberger Cancer Center, and 6National Institute of Mental Health Psychoactive Drug Screening Program, University of North
Carolina, Chapel Hill, North Carolina 27599, Departments of 7Cell Biology, 8Medicine, and 9Neurobiology, Duke University Medical Center, Durham, North
Carolina 27710, 10Department of Psychiatry, Division of Neurosciences, New England Primate Research Center, Harvard Medical School, Boston,
Massachusetts 02115, 11Division of Neuroscience, University of Edinburgh, Edinburgh EH8 9JZ, United Kingdom, and 12Genes to Cognition Programme,
Wellcome Trust Sanger Institute, Cambridge CB10 1SA, United Kingdom
Here, we report that postsynaptic density protein of 95 kDa (PSD-95), a postsynaptic density scaffolding protein, classically conceptual-
ized as being essential for the regulation of ionotropic glutamatergic signaling at the postsynapticmembrane, plays anunanticipated and
essential role in mediating the actions of hallucinogens and atypical antipsychotic drugs at 5-HT2A and 5-HT2C serotonergic G-protein-
coupled receptors. We show that PSD-95 is crucial for normal 5-HT2A and 5-HT2C expression in vivo and that PSD-95 maintains normal
receptor expression by promoting apical dendritic targeting and stabilizing receptor turnover in vivo. Significantly, 5-HT2A- and 5-HT2C-
mediated downstream signaling is impaired in PSD-95null mice, and the 5-HT2A-mediated head-twitch response is abnormal. Further-
more, the ability of 5-HT2A inverse agonists to normalize behavioral changes induced by glutamate receptor antagonists is abolished in
the absence of PSD-95 in vivo. These results demonstrate that PSD-95, in addition to the well known role it plays in scaffolding macro-
molecular glutamatergic signaling complexes, profoundly modulates metabotropic 5-HT2A and 5-HT2C receptor function.
Introduction
Known hallucinogens include lysergic acid diethylamide (LSD)-
like hallucinogens such as mescaline, LSD, psilocin, and N,N-
dimethyltryptamine (Nichols, 2004) and non-LSD-like halluci-
nogens such as salvinorin A (Roth et al., 2002). 5-HT2A serotonin
receptors, which represent themain site of action of the LSD-type
hallucinogens (Glennon et al., 1984), are most heavily expressed
in the apical dendrites and soma of pyramidal neurons in cortical
layers II, III, V, and VI (Willins et al., 1997; Jakab and Goldman-
Rakic, 1998), and knockout and tissue-specific rescue studies in-
dicate that cortical 5-HT2A receptors are themain site of action of
hallucinogens (Gonza´lez-Maeso et al., 2007). Moreover, the
5-HT2A inverse agonist property of atypical antipsychotic drugs is
thought to be an essential feature of their therapeutic actions
(Meltzer et al., 1989; Roth et al., 2004a; Gray and Roth, 2007).
The closely related 5-HT2C serotonin receptors are located
primarily in choroid plexus, striatum, and hippocampus (Molin-
eaux et al., 1989; Clemett et al., 2000; Lo´pez-Gimenez et al.,
2002). 5-HT2C receptors are unique among G-protein-coupled
receptors (GPCRs) in that they are post-transcriptionally edited
(Burns et al., 1997), a process which affects constitutive activity
(Niswender et al., 1999) and the efficiency of G-protein coupling
in a functionally selectivemanner (Price and Sanders-Bush, 2000;
Berg et al., 2001; Urban et al., 2007). A number of drugs targeting
5-HT2C receptors have been shown to be efficacious in animal
models of schizophrenia, obsessive–compulsive disorder
(OCD), depression, and obesity (Dunlop et al., 2005, 2006; Sard
et al., 2005; Gray and Roth, 2007; Marquis et al., 2007).
Previous studies by our lab and others have demonstrated that
the 5-HT2A and 5-HT2C receptors, which are essential for the
actions of atypical antipsychotic drugs and LSD-like hallucino-
gens (Roth et al., 2004a;Gonza´lez-Maeso et al., 2007; Berger et al.,
2009), can interact in vitro via a canonical type I postsynaptic
density protein of 95 kDa (PSD-95)/Dlg/ZO-1 (PDZ)-binding
motif (Be´camel et al., 2002, 2004; Xia et al., 2003a) with PSD-95,
a PDZ domain-containing scaffolding protein (Chen et al., 2000;
Kim et al., 2006;Nicoll et al., 2006) that is an essential regulator of
ionotropic glutamatergic neuronal signaling (Migaud et al., 1998;
Sheng and Kim, 2002; Ehrlich andMalinow, 2004; Schluter et al.,
2006; Xu et al., 2008). These in vitro data suggest that PSD-95
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could play a critical role in regulating 5-HT2A and 5-HT2C recep-
tors in neurons in vivo, tethering these receptors to the plasma
membrane and regulating their trafficking and function. In this
study, we show that genetic deletion of PSD-95 leads to profound
alterations in 5-HT2A and 5-HT2C receptor targeting, expression,
and signaling. We also show that these 5-HT receptor–PSD-95
interactions are essential for the normal function of the 5-HT2A
and 5-HT2C receptors, including their abilities to mediate hallu-
cinogen and atypical antipsychotic drug actions in vivo. Our find-
ings provide new insights into the precise subcellular site(s) of
action of hallucinogens and atypical antipsychotic drugs, as well
as implicate PSD-95 as an important regulator of metabotropic
5-HT2A and 5-HT2C receptor function.
Materials andMethods
Mice. A detailed description of how the PSD-
95nullmice were generated will be reported in a
future publication (M. I. Arbuckle, N. H.
Komiyama, L. H. Forsyth, M. Bence, J. A.
Ainge, E. R. Wood, H. J. Carlisle, T. J. O’Dell,
and S. G. N. Grant, unpublished observations).
Briefly, PSD-95null mice were made by deleting
the guanylate kinase (GK) domain of the pro-
tein. This results in an almost complete absence
of PSD-95 mRNA (5.7% of wild-type levels,
as assessed by gene microarray). Previous stud-
ies with these mice using two different antibod-
ies raised against epitopes N terminal to the GK
domain of PSD-95 detected no PSD-95 protein
whatsoever in the mutant mice (Yao et al.,
2004). Our immunochemical studies confirm
these findings (Fig. 1A). All experiments were
approved by the Institutional Animal Care and
Use Committee at Case Western Reserve Uni-
versity or the University of North Carolina,
Chapel Hill. Mice were housed under standard
conditions—12 h light/dark cycle and food and
water ad libitum.
Immunochemistry. The following antibodies
and dilutions were used: mouse anti-5-HT2A
(PharMingen/BD Biosciences), 1:500 (sec-
tions), 1:1000 (neurons); mouse anti-PSD-95
(Upstate Biotechnology), 1:1000; mouse anti-
5-HT2C D-12 (Santa Cruz Biotechnology),
1:500; rabbit anti-microtubule-associated pro-
tein 2 (MAP2; Millipore Bioscience Research
Reagents), 1:1000; rabbit anti-green fluorescent
protein (GFP) A11122 (Invitrogen), 1:1000;
rabbit anti-c-fos PC38 (Calbiochem), 1:1000;
Alexa Fluor 488 goat anti-mouse or goat anti-
rabbit, and Alexa Fluor 594 goat anti-mouse or
goat anti-rabbit (Invitrogen), 1:200. For immu-
nochemistry on brain tissue sections, PSD-
95wildtype and PSD-95null mice were perfused
with 4%paraformaldehyde in 1PBS and their
brains harvested and placed overnight in 4%
paraformaldehyde in 1 PBS at 4°C. Over the
next night, brainswere placed in 30% sucrose in
1 PBS until they sank, then frozen on dry ice
and stored at80°C. Sections were either free-
floating in 1 PBS (one or two sections per well
in a 24-well plate) or thaw-mounted onto
coated microscope slides, and they were then
permeabilized with 0.3% Triton in 1 PBS for
15–20 min. For immunochemistry on cultured
cortical neurons, 4 d in vitro (DIV) neurons
were washed twice with 1 PBS, fixed in 4%
paraformaldehyde in 1 PBS for 30 min, then
washed twice more with 1 PBS before perme-
abilizing. Blocking was performed using 5% milk in 1 PBS for 1–2 h.
Primary antibodies were incubated in 5% milk in 1 PBS at room tem-
perature for 2 h or overnight at 4°C while shaking. Sections were then
washed three times in 1 PBS (10 min for each wash). Secondary anti-
bodies were incubated in 5%milk in 1PBS at room temperature for 1 h
in the dark, while shaking. Sections were washed three times in 1 PBS
(10 min for each wash). Free-floating sections and neuronal coverslips
were transferred to a microscope slide and mounted for fluorescence
microscopic visualization.
Saturation radioligand binding. For saturation binding assays, brain
regions weremicrodissected and frozen on dry ice, then stored at80°C.
A Tissue Tearor (BioSpec Products) was used to homogenize tissue (10 s,
15,000 rpm) in 2ml of standard binding buffer (SBB; 50mMTrisHCl, pH
Figure 1. Genetic deletion of PSD-95 results in a selective loss of 5-HT2A and 5-HT2C receptors. A, 5-HT2A and PSD-95 double-
label immunochemistry in medial prefrontal cortex of PSD-95wildtype and PSD-95 null mice shows a large reduction in 5-HT2A
receptor expression in null mice (N 3 littermate pairs). B, 5-HT2C immunochemistry in PSD-95
wildtype and PSD-95 null striatum
and hippocampus reveals that 5-HT2C receptor expression is almost completely abolished in the absence of PSD-95 in both
striatum and hippocampus (N 3 littermate pairs). C, Comparison of Bmax estimates for the 5-HT2A receptor (N 4 littermate
pairs) and the 5-HT1A receptor (N 5 littermate pairs) in PSD-95
wildtype and PSD-95 null cortices.Bmax estimateswere obtained by
performing [ 3H]-ketanserin (5-HT2A) and [
3H]-WAY100635 (5-HT1A) saturation binding on microdissected and homogenized
cortical tissue. Quantitation showed an40% reduction in 5-HT2A expression and no change in 5-HT1A expression in the cortices
of PSD-95 null mice. D, Comparison of Bmax estimates for the 5-HT2C receptor (N 3; tissue from 3 animals was pooled for each
measurement, for a total of 9 animals, all littermate pairs) and 5-HT1A receptor (N 6 littermate pairs) in PSD-95
wildtype and
PSD-95 null hippocampi. Bmax estimates were obtained by performing [
3H]mesulergine saturation binding in the presence of 100
nM spiperone to block the vast majority of 5-HT2A receptors (5-HT2C) and [
3H]-WAY100635 saturation binding (5-HT1A). Quanti-
tation showed an almost 70% reduction in 5-HT2C expression and no change in 5-HT1A expression in hippocampus in the absence
of PSD-95. All saturation binding was analyzed using nonlinear least squares fitting. Bmax data are presented as means SEM;
*p 0.05, **p 0.01, ***p 0.001; one-tailed unpaired t test.
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7.4; 10 mM MgCl2; 0.1 mM EDTA). Homogenized tissue was spun for 10
min at 26,000  g (4°C) and the SBB removed. The pellet was resus-
pended in 1 ml of SBB and transferred to a 1.7 ml Eppendorf tube, then
spun at top speed in a microcentrifuge for 5 min at 4°C. The SBB was
removed, and the pellet was either used immediately for binding or
stored at 80°C until use. Saturation binding assays were performed
with the homogenized brain tissue and [3H]-ketanserin (5-HT2A, cor-
tex); [ 3H]-mesulergine plus 100 nM spiperone (5-HT2C, hippocampus);
or [ 3H]-WAY100635 (5-HT1A, cortex, hippocampus), then incubated in
SBB for 1.5 h. The following [3H] concentrations were used: 8 nM, 6 nM,
4 nM, 2 nM, 1.5 nM, 1.0 nM, 0.5 nM, 0.25 nM (5-HT2A and 5-HT2C), or 2 nM,
1.2 nM, 0.8 nM, 0.4 nM, 0.2 nM, 0.1 nM, 0.05 nM, 0.025 nM (5-HT1A), all in
duplicate for total and nonspecific (four reactions at each concentration
for each brain sample in which receptor was measured). Nonspecific
binding was determined by incubating the reactions with 8M ritanserin
(5-HT2A and 5-HT2C) or 10 M 5-HT (5-HT1A). For 5-HT2C measure-
ments, three samples were pooled for each assay. Bradford protein assays
were performed to normalize Bmax determinations to the amount of
protein in each assay. Reactions were harvested by vacuum filtration
through glass filters (3 ice-cold 50 mM Tris, pH 7.4; pH 6.9 at room
temperature) and counted by liquid scintillation using a Perkin-Elmer
Tri-Carb 2800TR.Microsoft Excel andGraphpad Prismwere used for all
data analysis.
EEDQ. EEDQ (N-ethoxycarbonyl-1,2-ethoxydihydroquinolone; dis-
solve EEDQ in 100% ethanol, than dilute 1:3 in saline) was injected
intraperitoneally at a dose of 10 mg/kg. Mice were killed at 1, 2, 3, 5, 7,
and 13 d after EEDQ treatment, and the 5-HT2A Bmax was measured by
saturation binding. Receptor production was assumed to be a zero-order
process and receptor trafficking a first-order process (Pinto and Batta-
glia, 1994). Thus, the equation derived to model receptor recovery was
[Bmax]t [Bmax]ss(1 e
kt), where [Bmax]t is the amount of receptor at
time t, [Bmax]ss is the steady state Bmax after the receptors have recovered,
k is the rate constant for receptor turnover (inverse days, or d1), and t is
the time at which [Bmax]t was measured in days. This model was fit by
nonlinear least squares regression to a plot of the average Bmax value at
each time point.
Quantitative reverse transcription-PCR.Trizol (Invitrogen)was used to
extract RNA from microdissected cortical tissue. RNA (10 g) was
treated with DNase (DNA-free; Ambion), and 2g of the DNase-treated
RNA was added to a reverse transcription (RT) reaction which was per-
formed using the Superscript III RNase H Reverse Transcriptase kit (In-
vitrogen) with oligo-(dT)12–18 primers (Invitrogen). IQ SYBRGreen Su-
permix (Bio-Rad) was used in a 7300 RT-PCR system (Applied
Biosystems) for quantitation. All steps were performed according to
manufacturer’s instructions.
Microarray experiment. RNA was extracted from microdissected cor-
tical tissue using Trizol (Invitrogen). The gene chip assay was performed
by the Gene Expression and Genotyping Core Facility at the Case Com-
prehensive Cancer Center using the Affymetrix Genechip Mouse Ge-
nome 430 2.0 Array. Data were analyzed using the Affymetrix Genechip
Operating Software, version 1.4.0.036.
5-HT2CmRNA editing.Microdissected hippocampal tissuewas pooled
by genotype and used to generate cDNA as described above. The follow-
ing primers were used to generate a PCR fragment (containing the edited
site) that was 327 base pairs in length that was then inserted into the
BamHI/EcoRI sites of pcDNA3: forward primer: 5AAA GGATCC TGT
GCT ATT TTC AAC TGC GTC CAT CAT G 3; reverse primer: 5AAA
GAATTCCGGCGTAGGACGTAGATCGTTAAG3 (Du et al., 2006).
Each bacterial colony resulting from transformation of the ligation prod-
uct represents a transcript. Clones were miniprepped and sequenced to
determine the extent of editing for each transcript.
Cortical neuronal cultures. Cortical neurons were prepared from post-
natal (P) day 0.5 mouse pups as described previously (Ahlemeyer and
Baumgart-Vogt, 2005). Briefly, cortex was microdissected in Mg2
HBSS under a dissectingmicroscope and incubated at 37°C for 20min in
neurobasal medium containing 0.1% papain and 0.02%BSA. The super-
natant was removed and the tissue was then mechanically triturated in
neurobasal medium. The supernatant was transferred to a new sterile
Eppendorf, leaving the aggregates, and spun down at 200 g for 10min.
The supernatant was discarded and the pellet resuspended in pre-
equilibrated (to 37°C and 5% CO2) neurobasal medium containing B27
supplement, antibiotics, and 0.5 mM glutamine, and plated on coverslips
coated with low molecular weight poly-L-lysine. Immunochemical ex-
periments were performed at 4–5 DIV.
Lentiviral preparation. PSD-95was cloned into the Flip, ubiquitin pro-
moter, GFP, and woodchuck hepatitis virus response element (FUGW)
lentiviral vector (Lois et al., 2002) by ligating aBclI-digested PSD-95 PCR
fragment into the BamHI site 5 to the GFP (forward primer: 5-AAA
TGA TCA ATG GAC TGT CTC TGT ATA GTG ACA ACC-3; reverse
primer: 5-AAA TGA TCA GAG TCT CTC TCG GGC TGG GAC CCA-
3). Site-directed mutagenesis was performed to mutate away the stop
site that results from theBclI–BamHI ligation at the 3 end of PSD-95 and
shift the reading frame so that PSD-95 is in frame with GFP (sense prim-
er: 5-GCC CGA GAG AGA CTC TTA TTT CCC CCG GGG GTA CCG
GT-3; antisense primer: 5-ACC GGT ACC CCC GGGGGA AAT AAG
AGT CTC TCT CGGGC-3). Fugene6 (50l Fugene6, 10g total DNA
per 10 cm plate) was used to cotransfect HEK293T cells with three plas-
mids [FUGW/	8.9 HIV-1/VSVG (vesicular stomatitis viral glycopro-
tein)] in a ratio of 3.3/2.5/1. Lentivirus-containing media was collected
48 h later and filtered through a 0.45 M filter to remove cellular debris.
Lentivirus was aliquoted and frozen at80°C until use. Cortical neurons
were infected with 20–50 l GFP or PSD-95 GFP lentivirus at 2 DIV.
Immunochemistry was performed at 5 DIV.
MK-212-induced c-fos in hippocampus. Mice were injected intraperi-
toneally with 5mg/kgMK-212 in 0.9% sterile NaCl or vehicle. Forty-five
minutes later, they were perfused with 4% paraformaldehyde. Frozen
sections (Bregma1.34 mm to Bregma2.7 mm) were thaw mounted
onto frosted slides and then used for immunochemistry and subsequent
c-fos quantitation.
DOI-induced head-twitch.Mice were injected intraperitoneally with 5
mg/kg of DOI [(2,5-dimethoxy-4-iodophenyl)-2-aminopropane]. The
number of head-twitches was counted and recorded in 5min bins for the
half hour period immediately after injection. A subset of the 5 mg/kg
injections (N  7) were counted by two observers, one of whom was
blinded to the genotype. A comparison of the results produced by the two
different observers was not significantly different (data not shown). All
the other head-twitch experiments were performed by one blinded
observer.
8-OH-DPAT-induced hypothermia. Rectal temperature was measured
using the TH-5 Thermalert Monitoring Thermometer (Physitemp In-
struments) equipped with a RET-3 probe. The probe was sterilized with
70% ethanol and covered with vaseline before measuring each mouse’s
temperature. Mice were then injected intraperitoneally with 5 mg/kg
8-OH-DPAT [8-hydroxy-2-(di-n-propylamino)tetralin], and rectal
temperature was measured again 20 min later.
Western blot. DOI or vehicle was injected intraperitoneally, with light
restraint tominimize stress effects, and thenmicewere killed 15min later
by cervical dislocation. Microdissection was performed on ice as quickly
as possible. Tissue was homogenized in 400 l of SBB plus protease and
phosphatase inhibitors and 5% glycerol. Tissue was spun for 10 min at
20–25,000 g. The supernatant, which contains the proteins of interest,
was collected and a protein assay performed for quantitation. SDS was
added to 25g of protein boiled for 5 min to denature and then used for
Western blots. The following antibodies were used forWestern blot, all at
a 1:1000 dilution: rabbit polyclonal p-ERK1/2 (9101L; Cell Signaling
Technology), rabbit polyclonal ERK1/2 (9102L; Cell Signaling Technol-
ogy), p-GSK3 (9331; Cell Signaling Technology), and rabbit monoclo-
nal GSK3 (9315; Cell Signaling Technology).
Prepulse inhibition. All prepulse inhibition (PPI) experiments were
performed at theMouse Behavioral Phenotyping Laboratory Core Facil-
ity in the Neurodevelopmental Disorders Research Center at the Univer-
sity of North Carolina, Chapel Hill using the SR-Lab (San Diego Instru-
ments). Briefly, mice were placed in a small, Plexiglas cylinder housed
within a large sound-proofed chamber. The cylinder is seated on a piezo-
electric transducer which quantifies movement-induced vibrations. The
SR-Lab chamber also contains a light, fan, and loudspeaker for acoustic
stimuli. Calibration of 70 dB background sound levels and prepulse
acoustic stimuli was performed with a digital sound level meter (San
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Diego Instruments). Each session consisted of a 5min habituation period
followed by 42 trials of seven types—no stimulation, 120 dB acoustic
stimulus (AS50), and five different prepulse stimuli ranging from 4 dB
over back ground (PP74) to 20 dB over background (PP90). The trial
types were performed in six sets of seven, with the trial type order in each
set randomized. Intertrial intervals were 10–20 s, with an average interval
of 15 s. The AS50 was 40 ms long, whereas the prepulse stimulus was 20
ms long and occurred 100ms before the onset of the startle stimulus. The
sample window for measuring startle amplitude was 65 ms. The formula
used to calculate percentage PPI was: ((AS50  startle after prepulse)/
AS50)  100. Mice were injected with vehicle, phencyclidine (PCP), or
antipsychotic and PCP before being placed in the PPI chamber. When
treated with vehicle or PCP, mice were immediately placed in the cham-
ber. When treating with antipsychotic, mice were injected with antipsy-
chotic 15 min before injecting PCP, after which mice were immediately
placed in the chamber. There was a 1 week washout period between
treatments.
PCP-induced hyperlocomotion. Locomotion was measured in a 1 h
session in an open field chamber (40 40 30 cm) crossed by a grid of
photobeams (VersaMax system; AccuScan Instruments). The mice were
injectedwith vehicle or SR46349B andplaced in the chamber for a 20min
acclimation period, and then they were injected with vehicle or PCP, and
locomotion was measured for 1 h. Mice were treated with vehicle, 6.0
mg/kg PCP, or 1.0 mg/kg SR46349B plus 6.0 mg/kg PCP. Mice were
allowed a 1 week washout period between treatments. The number of
photobeambreakswas counted during the 60min trial in 5min bins, and
a total distance traveled in centimeters was calculated from the beam
break counts.
Results
PSD-95 is essential for maintaining normal 5-HT2A and 5-
HT2C receptor expression in vivo
Previous studies demonstrated that PSD-95 interacts with
5-HT2A (Xia et al., 2003a,b; Be´camel et al., 2004) and 5-HT2C
(Be´camel et al., 2002) receptors in vitro and in vivo. Additionally,
ectopic expression of PSD-95 inhibits the agonist-mediated in-
ternalization of the 5-HT2A receptor (Xia et al., 2003a) and pro-
motes desensitization of 5-HT2C receptors (Gavarini et al., 2006)
in vitro. Eliminating the type I PDZ ligand motif abrogates both
PSD-95 binding and functional activity in vitro (Xia et al.,
2003a,b). What, if any, effect PSD-95 might have in vivo is un-
known, although we predicted that PSD-95 is responsible for
proper targeting and synaptic membrane stabilization of 5-HT2A
and 5-HT2C serotonin receptors.
To test this prediction, we examined 5-HT2A and 5-HT2C re-
ceptor expression in PSD-95wildtype and PSD-95nullmice. As seen
in Figure 1A, PSD-95null mice exhibit very little apical dendritic
immunofluorescence compared with PSD-95wildtype littermate
controls. We also performed saturation binding experiments
with [3H]-ketanserin on microdissected cortices to obtain a
quantitative estimate of 5-HT2A receptor levels in null mice (Fig.
1C). We determined that, consistent with our immunohisto-
chemical findings, PSD-95null mice exhibit a significant reduc-
tion in 5-HT2A receptor expression.
As shown in Figure 1B, PSD-95null animals displayed even
larger decrements of striatal and hippocampal 5-HT2C receptors
as assessed by a 5-HT2C-selective antibody. Saturation binding
isotherms using [3H]-mesulergine under conditionswhich selec-
tively label 5-HT2C receptors (see Materials and Methods) dem-
onstrated a 72% reduction in 5-HT2C receptor expression levels
in the hippocampus (Fig. 1D).
PSD-95 regulates serotonin receptor turnover
We next examined several potential mechanisms which might
account for the PSD-95-mediated modulation of 5-HT2A and
5-HT2C receptor expression. These included the following: (1)
nonspecific effects on the serotonin system; (2) PSD-95-
mediated regulation of 5-HT receptor transcription and/or a
generalized disruption of the machinery essential for neuronal
regulation of receptors; (3) PSD-95-mediated alterations in sero-
tonin receptor mRNA editing; and (4) alterations in serotonin
receptor turnover. Each of these possibilities will be dealt with in
turn.
We first examined the possibility that genetic deletion of
PSD-95 leads to generalized serotonergic system dysfunction
leading to a reduction in serotonin receptor levels. We examined
this first possibility bymeasuring the expression of a related 5-HT
receptor which is also highly expressed in cortex and hippocam-
pus but lacks a PDZ-ligand motif—the 5-HT1A receptor. As our
saturation binding experiments using [3H]-WAY100635 indi-
cate, 5-HT1A expression levels were unchanged in PSD-95
null
mice in both cortex (Fig. 1C) and hippocampus (Fig. 1D). These
results indicate that genetic deletion of PSD-95 does not lead to a
generalized alteration in the serotonergic system.
To examine the unlikely possibility that deleting PSD-95 leads
to an alteration in 5-HT receptor gene transcription, we per-
formed quantitative RT-PCR to measure 5-HT2A and 5-HT2C
receptor mRNA levels. We found that 5-HT2A mRNA levels are
unchanged in cortex (Fig. 2A), and 5-HT2C mRNA levels are
unchanged in hippocampus (Fig. 2A). To further assess the role
of PSD-95 inmodulatingmRNA levels more broadly, or the pos-
sibility that compensatory changes in global gene expression oc-
cur in null animals and that these compensatory changes cause
the observed phenotypes, we performedwhole-genomemicroar-
ray analysis on cDNA prepared from PSD-95wildtype and PSD-
95null cortices. Overall, there were few differences in transcript
levels, and only 28 genes (27 genes decreased, 1 gene increased)
appear to be modulated greater than twofold in the absence of
PSD-95—none of which are GPCRs or are expected to modulate
the expression of 5-HT receptors (supplemental Table 1, avail-
able at www.jneurosci.org as supplemental material). Thus, the
whole genome microarray data are more consistent with a role
for PSD-95 in post-transcriptional/post-translational regulation
of 5-HT2A and 5-HT2C receptors.
Interestingly, 6 of the 28 genes, out of45,000 transcripts on
themicroarray, have previously been reported to be induced after
hallucinogen administration (Table 1) (Nichols and Sanders-
Bush, 2002; Gonza´lez-Maeso et al., 2003). In one study of tran-
scripts induced by 5-HT2A agonists, only 3 of 13 transcripts
shown to be changed by agonist administration were specific to
hallucinogenic agonists (Gonza´lez-Maeso et al., 2003). Two of
these three genes, egr2 and per1, are downregulated in the absence
of PSD-95 according to our microarray data, which is consistent
with a possible role of PSD-95 in mediating some 5-HT2A signal-
ing pathways, particularly those related to hallucinogen actions.
The 5-HT2C receptor undergoes mRNA editing which modu-
lates its constitutive activity, G-protein coupling efficiency, and
expression (Niswender et al., 1999; Price and Sanders-Bush,
2000). It is, therefore, conceivable that changes in 5-HT2C recep-
tor expression are secondary to altered editing of 5-HT2C mR-
NAs. To examine this possibility, we examined RNA editing at all
possible sites in PSD-95wildtype and PSD-95null hippocampal tis-
sue, and we found that there is no change in the frequency of
editing at any of the five sites (Fig. 2B). Furthermore, there is no
significant change in the proportions of 14 of the 15 different
isoforms detected in the PSD-95null mice compared with PSD-
95wildtype mice (Fig. 2C,D). An increase in PSD-95null mice of 1
isoform out 15, the valine-serine-isoleucine (VSI) isoform, is in-
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consistent with a role for mRNA editing in
downregulating 5-HT2C receptors in PSD-
95null mice. These findings indicate that
neither transcriptional nor post-
transcriptional mechanisms (i.e., RNA ed-
iting) can account for the large effect that
genetic deletion of PSD-95 has on the ex-
pression of 5-HT2A and 5-HT2C receptors.
Our data clearly point to the fourth
prediction that PSD-95 is exerting its effect
on the 5-HT2A and 5-HT2C receptors by
regulating their turnover. Implicit in our
hypothesis is that in the absence of PSD-
95, 5-HT2A and 5-HT2C receptorswill have
greater access to intracellular trafficking
machinery, or will enter alternative traf-
ficking pathways, leading to higher rates of
receptor turnover. To assess the rates of
receptor turnover in PSD-95wildtype and
PSD-95null animals, we took advantage of
the properties of EEDQ, which binds irre-
versibly to 5-HT2A receptors (surface and
intracellular), occluding them from recog-
nition by their ligands after EEDQ treat-
ment. By treating mice with EEDQ and
modeling the rate of receptor recovery
over time, one can measure the rate of
5-HT2A receptor turnover in vivo (Pinto
and Battaglia, 1994).
For these studies, we injectedmice once
with EEDQ (10 mg/kg), a dose that
achieves 90% irreversible blockade of
5-HT2A receptors, and performed satura-
tion binding experiments at different time
points after EEDQ treatment to measure
the recovery rate of 5-HT2A receptors. If
5-HT2A receptors in null mice have a
higher rate of turnover, then the rate con-
stant of recovery (Pinto and Battaglia,
1994) should be higher in thesemice. Con-
sistent with this prediction, the modeled
receptor recovery in PSD-95wildtype and
PSD-95null mice (Fig. 3A,B) showed that
the rate constant, k (d1), was substan-
tially higher in null mice. These findings
indicate that genetic deletion of PSD-95
accelerates 5-HT2A receptor turnover in
vivo. Attempts to perform similar studies
with 5-HT2C receptors were unsuccessful
because of the exceedingly low levels of
5-HT2C receptors expressed in PSD-95
null
mice.
PSD-95 is required for the polarized sorting of 5-HT2A
receptors to pyramidal neuron apical dendrites
Another important aspect of our hypothesis focuses on 5-HT2A
receptors and the prediction that PSD-95 is crucial for proper
targeting to the apical dendrites. Previous studies showed that
mutating the PDZ ligandmotif prevents dendritic targeting of the
5-HT2A receptor in vitro (Xia et al., 2003b). To determine if
PSD-95 is one of the PDZ-domain proteins responsible for the
preferential dendritic targeting of 5-HT2A receptors, we exam-
ined the ability of 5-HT2A receptors to be sorted to neuronal
dendrites in cortical neurons prepared from PSD-95wildtype and
PSD-95null mice.
For these studies, we performed confocal immunofluorescent
studies of mouse cortical neurons for 5-HT2A receptors and the
dendritic marker MAP2 (Caceres et al., 1984). As Figure 4, A and
B, illustrates, neurons prepared from PSD-95null animals exhibit
significantly lower 5-HT2A receptor expression in both the neu-
ronal soma and dendrites—a finding consistent with our in vivo
data. To examine the impact of PSD-95 on dendritic trafficking,
we also calculated a 5-HT2A receptor cell body/dendrite expres-
sion (CB/D) ratio. If dendritic targeting is impaired in PSD-95null
neurons, we predicted that the CB/D ratio should be higher in
Figure2. Genetic deletionof PSD-95doesnot affectmRNA levels of 5-HT2A and5-HT2C receptors ormRNAeditingof the5-HT2C
receptor.A, Cortical 5-HT2A receptormRNA levels (N 4 littermate pairs; 11measurementswere performed for each animal) and
hippocampal 5-HT2C receptormRNA levels (N4 littermatepairs; 5measurements for eachanimal) normalized to-actinmRNA
levels asmeasured by quantitative RT-PCR. There are no changes in 5-HT2AmRNA levels and no changes in 5-HT2CmRNA levels in
the absence of PSD-95. B, 5-HT2C mRNA editing frequencies at five edited sites. The frequency of editing at the five sites is not
significantly different in PSD-95 null mice. C, D, Frequencies of the different edited isoforms detected (wildtypes, N 94; nulls,
N 93). Fifteen isoforms were detected, and 14 of them were not significantly altered in the absence of PSD-95. There is a
significant increase in the proportion of the VSI isoform in PSD-95 nullmouse hippocampus. All mRNA editing data are plotted as
the frequency expressed as a fraction of the total, the SEM. NormalizedmRNAmeasurements are presented asmeans SEM;
*p 0.05, **p 0.01, ***p 0.001; one-tailed unpaired t test for the comparison of mRNA levels and one-way ANOVA
followed by Newman–Keuls post hoc tests for comparison of the mRNA editing measurements.
Table 1. Genes of interest affected in PSD-95 knock-out mice
Gene of interest Alternate names Downregulation as percentage of wild type
Arcb rg3.1 36.6
egr2a,b krox20; ngf1b; zfp-25; zfp-6 38.6
per1a rigui 42.0
Jun-Ba 46.7
Nr4a1a N-10; gfrp; gfrp1; hbr-1; hmr; np10; tr3; nur77; tis1 50
Homer1ab,c 35.3
Six transcripts that are downregulated in PSD-95null mice have been reported to be induced after hallucinogenic drug administration in mice. Most are
immediate early genes, which is consistent with a role for PSD-95 in regulating 5-HT2A signaling.
aGonzález-Maeso et al., 2003; Yuen et al., 2003.
bNichols and Sanders-Bush, 2002.
cThe gene previously reported to be upregulated after hallucinogen administration is ania3, a closely related isoform that differs only in the 5 untranslated
region and a few amino acids at the C terminus.
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these neurons, as impairment of 5-HT2A trafficking to dendrites
should result in a relative accumulation of receptors in the neu-
ronal cell body. As predicted, Figure 4B confirms that the CB/D
ratio is higher in PSD-95null neurons.
If PSD-95 is essential for 5-HT2A expression and sorting to the
dendrites, reintroduction of PSD-95 should increase receptor ex-
pression in both the neuronal soma and dendrites. Furthermore,
PSD-95 re-expression should decrease the CB/D ratio, represent-
ing an increase in dendritic targeting of receptor. To assess the
effect of re-expression of PSD-95 on 5-HT2A expression and tar-
geting, we generated PSD-95–GFP lentivirus and a control GFP
lentivirus and infected cortical neuronal cultures prepared from
PSD-95null animals (Fig. 5A). PSD-95–GFP expression led to an
2-fold increase in cell body 5-HT2A expression and an5-fold
increase in dendritic 5-HT2A expression compared with GFP ex-
pression in neurons prepared from the same PSD-95null animals
(Fig. 5B). Furthermore, as predicted, the CB/D ratio is greatly
decreased in PSD-95null neurons expressing PSD-95–GFP com-
pared with those expressing the control GFP (Fig. 5B).
PSD-95 is required for 5-HT2C signaling in vivo
Having provided strong evidence that PSD-95 profoundly regu-
lates the expression of 5-HT2C receptors, we next examined the
consequences of knocking out PSD-95 on 5-HT2C function in
vivo. It is well established that c-fos is an immediate early gene
(IEG) which is transcribed after GPCR activation (Lo andWong,
2006) and which is useful as a general marker of neuronal activity
(Chaudhuri, 1997). To examine the consequences of genetic de-
letion of PSD-95 on signaling downstream of the 5-HT2C recep-
tor and on neural activity, we treated mice with MK-212, a
5-HT2C-selective agonist (Thomsen et al., 2008), and assessed
induction of c-fos in the hippocampus. Significantly, we found
that the number of c-fos-positive cells after MK-212 treatment
was greatly reduced in PSD-95null animals in a number of hip-
pocampal subregions (Fig. 6A,B; supplemental Fig. S1, available
at www.jneurosci.org as supplemental material). Our finding
that MK-212 induces the largest c-fos response in the dentate
gyrus region of the hippocampus is in accordance with previous
studies (Campbell and Merchant, 2003). This reduction did not
appear to be related to alterations in hippocampalmorphology or
volume, as cresyl violet staining does not reveal any gross abnor-
malities in the absence of PSD-95 (supplemental Fig. S2, available
at www.jneurosci.org as supplemental material). Furthermore,
the thickness of the stained regions [in
CA1–CA3, the pyramidal layer; in dentate
gyrus (DG), the granular layer] was un-
changed in PSD-95null mice (supplemen-
tal Fig. S2, available at www.jneurosci.org
as supplemental material). This decrease
in c-fos induction seen in all hippocampal
regions measured was highly significant
(Fig. 6C) and indicates that genetic dele-
tion of PSD-95 greatly attenuates 5-HT2C
signaling in vivo.
PSD-95 is essential for hallucinogen
actions in vivo
We also predicted that the alterations in
5-HT2A expression induced by deleting
PSD-95 should lead to a reduction in hal-
lucinogen actions in vivo. Although a
number of animal models have been pro-
posed for studying hallucinogen action in
rodents (Nichols, 2004), head-twitch behavior has been shown to
be the most specific for hallucinogenic action in that nonhalluci-
nogenic 5-HT2A agonists such as lisuride do not induce the be-
havior (Gonza´lez-Maeso et al., 2007). PSD-95wildtype and PSD-
95null mice were injected with a 5 mg/kg dose of the prototypical
5-HT2A hallucinogen 1-(4-iodo-2,5-dimethoxyphenyl)propan-
2-amine hydrochloride (Imamura et al., 2002). We found that
there was a large and significant decrease in DOI-induced head-
twitch in PSD-95null animals compared with PSD-95wildtype ani-
mals (Fig. 7A). Head twitches are virtually nonexistent in both
PSD-95wildtype andPSD-95null animals after saline treatment (0–2
per 30 min; data not shown). In contrast, 8-OH-DPAT, which is
known to induce hypothermia via agonist action at 5-HT1A re-
ceptors in the CNS (Martin et al., 1992), leads to the same de-
crease in temperature in both PSD-95wildtype and PSD-95nullmice
(Fig. 7A). Together, the findings suggest that PSD-95 selectively
affects behaviors mediated by 5-HT2A receptors.
Given the reduction in DOI-induced head-twitch seen in the
absence of PSD-95 in vivo, we also predicted that 5-HT2A-
mediated signaling would be reduced or absent in PSD-95null
mice. The 5-HT2A receptor has been shown to signal through a
large number of canonical (phospholipaseC) andnoncanonical
(phospholipase A2, phospholipase D, etc.) pathways (Nichols,
2004). The evidence thus far suggests that hallucinogen action is
not correlated with canonical signaling pathways, since both hal-
lucinogenic and nonhallucinogenic agonists at the 5-HT2A recep-
tor activate those pathways with similar potencies (Nichols,
2004). 5-HT2A agonists have been shown to activate ERK1/2 via a
number of different mechanisms (Hershenson et al., 1995;
Greene et al., 2000; Quinn et al., 2002; Go¨oz et al., 2006), and
5-HT2A agonists also lead to Akt activation (i.e., Akt phosphory-
lation) (Johnson-Farley et al., 2005). Phosphorylation of Akt
leads to phosphorylation of GSK3, which renders that protein
inactive (Beaulieu et al., 2008). Accordingly, we predicted that the
induction of phospho-ERK1/2 (pERK1/2) and phospho-GSK3
(p-GSK3) after treatment with DOI (5 mg/kg) would be re-
duced or absent in PSD-95nullmice (Li et al., 2004; Schmid et al.,
2008). Consistent with our prediction, we found that DOI was
unable to induce pERK1/2 or pGSK3 in PSD-95null mice (Fig.
7B–D). Thus, our evidence suggests that PSD-95 plays an impor-
tant role in mediating 5-HT2A downstream signaling, and its ab-
sence results in signaling and behavioral abnormalities.
Figure 3. Genetic deletion of PSD-95 leads to an accelerated turnover of 5-HT2A receptor protein. A and B represent fitted
curves modeling 5-HT2A receptor turnover in PSD-95
wildtype and PSD-95 nullmice, respectively (N 3–4 littermate pairs at each
data point). Visual inspection shows that steady-state levels for the 5-HT2A receptor are reached sooner in the absence of PSD-95,
suggesting accelerated turnover. The higher k in PSD-95 null cortex indicates a higher rate of receptor turnover in the absence of
PSD-95. Rate constant, k, is a nonleast squares fitted parameter of an equation modeling receptor recovery (for details, see
Materials and Methods), SEM; *p 0.05, **p 0.01, ***p 0.001; one-tailed unpaired t test.
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Deletion of PSD-95 renders atypical
antipsychotics ineffective
It has been recently demonstrated that
synaptic and behavioral measures of
dopamine-mediated synaptic plasticity are
also altered by genetic deletion of PSD-95
(Yao et al., 2004). We thus hypothesized
that the prototypical, gold standard atypi-
cal antipsychotic drug clozapine, whose
actions are mediated via inverse agonism
at 5-HT2A and 5-HT2C receptors (Meltzer
et al., 1989; Rauser et al., 2001) and by
weak D2/D3/D4-dopamine antagonism
(Roth et al., 2004b), would have an altered
activity in PSD-95null mice. In this regard,
the PCP-induced disruption of PPI is a
well accepted pharmacological model of
schizophrenia (Geyer et al., 2001; Linn and
Javitt, 2001). Importantly, clozapine pref-
erentially normalizes PCP-induced dis-
ruption of PPI in both rodents and mon-
keys, whereas typical antipsychotics like
haloperidol have little to no effect (Geyer
et al., 2001; Linn et al., 2003). As all the
published evidence suggests that 5-HT2A
receptors are important inmediating cloz-
apine’s reversal of the PCP-induced dis-
ruption of PPI (Yamada et al., 1999), we
predicted that clozapine would exhibit an
altered ability to inhibit PCP-induced dis-
ruption of PPI in PSD-95null mice.
To test this prediction, we injected lit-
termate pairs of PSD-95wildtype and PSD-
95nullmice with vehicle, PCP, or clozapine
plus PCP, followed by PPI assessment.
PCP significantly disrupted PPI at all pre-
pulse levels in PSD-95wildtype mice and at
two of the four prepulse levels in PSD-
95nullmice (Fig. 8A; supplemental Fig. S3,
available at www.jneurosci.org as supple-
mental material). Clozapine normalized
the PCP-induced deficit of PPI in PSD-
95wildtype mice while having no significant
effect in PSD-95null mice. As a control, we
also measured startle response and found
no significant effect of genotype on startle
response (AS50) with and without drug
treatments (supplemental Fig. S3, avail-
able at www.jneurosci.org as supplemental
material), and clozapine treatment alone
had no effect on PPI compared with
vehicle-treated mice (Fig. 8B). Thus, ge-
netic deletion of PSD-95 abolishes the antipsychotic-like actions
of clozapine.
Although the actions of clozapine in NMDA-antagonist-
based psychosis models such as PCP-induced disruption of PPI
are known to be 5-HT2A-mediated, clozapine is nonetheless a
pharmacologically “dirty” drug, with a high affinity for a number
of other receptors (Roth et al., 2004a). To more firmly establish
that 5-HT2A dysfunction is responsible for the abnormal
antipsychotic-like efficacy seen in the aforementioned clozapine
experiment, we used two selective antagonists of the 5-HT2A re-
ceptor, M100907 and SR46349B, which have been shown to be
effective in NMDA antagonist-based animal models of psychosis
(Varty et al., 1999) and in clinical studies of schizophrenic pa-
tients (Meltzer et al., 2004). If the impaired efficacy of clozapine is
because of 5-HT2A dysfunction, then 5-HT2A antagonists should
be ineffective as antipsychotics in multiple psychosis models. In
this experiment, PCP significantly disrupted PPI at 4 and 8 dB in
both PSD-95wildtype and PSD-95null mice (Fig. 8C). As predicted,
pretreatment withM100907 (0.5 mg/kg) or SR46349B (1 mg/kg)
normalized PCP-induced disruption of PPI in PSD-95wildtype
mice only, having no effect in PSD-95null mice (Fig. 8C). To
provide further evidence that antipsychotic-like efficacy medi-
Figure 4. 5-HT2A receptor expression and dendritic targeting is attenuated in neurons prepared from PSD-95
null mice. A,
Representative images of double-label immunochemistry performed on P0.5 cortical neurons of PSD-95wildtype and PSD-95 null
mice. The red arrows highlight the same dendritic process in all three images of each neuron. MAP2-positive dendrites display
reduced 5-HT2A receptor expression in the absence of PSD-95.B, Comparison of 5-HT2A receptor expression, normalized toMAP2
expression, in cell bodies and dendrites, and CB/D expression ratio, in PSD-95wildtype and PSD-95 null neurons. Quantitation of
5-HT2A receptors shows that in PSD-95
null neurons, expression is dramatically reduced in both neuronal soma and dendrites. The
increase in the CB/D ratio in PSD-95 null neurons suggests an impairment in dendritic targeting in the absence of PSD-95. N 3
littermate pairs, 17 neurons from each animal, for a total of 51 neurons measured per genotype. Data are presented as the
mean the SEM; *p 0.05, **p 0.01, ***p 0.001; one-tailed unpaired t test.
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ated by 5-HT2A receptors is impaired in the absence of PSD-95,
we examined the effect of SR46349B (1 mg/kg) in another widely
used animalmodel of psychosis, PCP-induced hyperlocomotion,
which is also normalized by atypical antipsychotics such as clo-
zapine (Gleason and Shannon, 1997; Geyer and Ellenbroek,
2003). As expected, SR46349B (1 mg/kg)
normalizes PCP-induced hyperlocomo-
tion in PSD-95wildtype but not PSD-95null
mice (Fig. 8D). Thus, our findings are very
consistent in showing that the genetic de-
letion of PSD-95 leads to 5-HT2A receptor
dysfunction which in turn prevents atypi-
cal antipsychotics from being therapeuti-
cally efficacious in animal models of
psychosis.
Discussion
The main finding of this study is that
PSD-95 is essential for serotonin receptor
function and hallucinogen and atypical
antipsychotic actions in vivo. These find-
ings suggest that in addition to its well
known modulatory effect on ionotropic
glutamatergic signaling, PSD-95 is re-
quired for normalmetabotropic serotonin
receptor function.We show that PSD-95, a
modular PDZ domain-containing protein
which scaffolds a wide range of proteins at
postsynaptic clusters, is an important reg-
ulatory partner for both 5-HT2A and
5-HT2C receptors in vivo. In the absence of
PSD-95, the 5-HT2A receptor has acceler-
ated receptor turnover kinetics and de-
creased targeting to the appropriate den-
dritic compartment, leading to a decrease
in total receptor expression and a concom-
itant decrease in 5-HT2A-mediated signal-
ing (p-ERK1/2 and p-GSK3) and behav-
iors (e.g., head-twitch response). In the
absence of PSD-95, the 5-HT2C receptor
exhibits a larger decrease in receptor pro-
tein expression and downstream signaling.
Finally, we show that, in the absence of
PSD-95, the prototypical atypical antipsy-
chotic drug clozapine, as well as the selec-
tive 5-HT2A antagonists M100907 and
SR46349B, are unable to mediate their
therapeutic effects in animal psychosis
models.
5-HT2C receptors, PSD-95, and
psychiatric disease
There is considerable evidence that
5-HT2C serotonin receptors regulate hip-
pocampal function. Genetic evidence
from 5-HT2C knock-out mice shows that
long-term potentiation (LTP) is impaired
in the dentate gyrus in the absence of
5-HT2C receptors (Tecott et al., 1998).
5-HT2C knock-out mice also exhibit de-
fects in behaviors thought to be mediated
by the dentate gyrus (Tecott et al., 1998)
and are more susceptible to spontaneous
and audiogenic seizures (Tecott et al.,
1995), which are known to involve limbic recruitment
(Wieraszko and Seyfried, 1993; Pereira et al., 2008).
Despite this evidence that 5-HT2C receptors modulate neuro-
nal function, nothing is known regarding their targeting and reg-
Figure5. ReintroductionofPSD-95rescues5-HT2Areceptorexpressionandtraffickingdeficits inPSD-95
nullcorticalneurons invitro.A,
Representative imagesofdouble-label immunochemistryperformedonP0.5 cortical neuronsofPSD-95nullmice infectedwitheitherGFP
lentivirus (top2 rowsofpanels) orPSD-95–GFP lentivirus (bottom2rowsofpanels).PSD-95nullneurons fromeachanimalwereplated in
twowells, one for GFP lentiviral infection and theother for PSD-95–GFP lentiviral infection. The yellowarrowshighlight dendritic 5-HT2A
receptor expression in an infected neuron. White arrows highlight 5-HT2A receptor expression in an uninfected neuron. GFP-infected
neurons display lowoverall 5-HT2A expression and lowdendritic targeting. In contrast, PSD-95–GFP-infectedneurons display a dramatic
increase inoverall 5-HT2A receptorexpressionandsubstantiallymore receptorappears tobe targeted to thedendritic compartment,both
comparedwith controlGFP-infectedneuronsandcomparedwithuninfectedneurons in the same field.B, Comparisonof5-HT2A receptor
expression incell bodiesanddendritesandtheCB/Dratio inGFP-andPSD-95–GFP-infectedPSD-95nullneurons. Expression isnormalized
to GFP or PSD-95–GFP. PSD-95–GFP leads to substantial rescue of 5-HT2A receptor expression compared with GFP-infected control
neurons.PSD-95–GFPaddback leads toasignificant reduction in theCB/Dratio comparedwithGFP-expressingcontrolneurons, suggest-
ing that PSD-95–GFP is rescuing dendritic targeting of 5-HT2A receptor expression. N 3 animals for each animal/lentivirus, and 10
infectedneurons fromeachanimal/lentivirusweremeasured (60neurons total).Dataarepresentedas themean theSEM;*p0.05,
**p 0.01, ***p 0.001; one-tailed unpaired t test.
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ulation of neuronal function. Our data
concerning the 5-HT2C receptor’s interac-
tion with, and regulation by, PSD-95 sug-
gests that the 5-HT2C receptor is present at
PSD-95-enriched neuronal domains
where it would be well placed to influence
neuronal excitability and synaptic proper-
ties and, therefore, brain electrical activity.
Although our studies focused on 5-HT2C
function in the hippocampus, the poten-
tial relevance of our findings to 5-HT2C
function in other brain regions is also of
interest. The 5-HT2C receptor has shown
promise as a target in the treatment of a
number of psychiatric disorders, including
in particular schizophrenia and obesity, al-
though it has been proposed that 5-HT2C
receptors may also play a role in the etiol-
ogy and treatment of OCD and depression
(Dunlop et al., 2005, 2006; Sard et al.,
2005; Gray and Roth, 2007; Marquis et al.,
2007). Thus, PSD-95 may play a role in
regulating 5-HT2C function in various dis-
ease states, although further study will be
needed to investigate this intriguing
possibility.
Implications of PSD-95 regulation of
hallucinogen action
Although it is known that hallucinogens
exert their effects via activation of the
5-HT2A receptor (Glennon et al., 1983),
the signaling processes underlying halluci-
nogen action are still poorly characterized.
Recent evidence suggests that cortical
5-HT2A receptors are required for halluci-
nogen actions, possibly by facilitating cor-
ticocortical activity (Gonza´lez-Maeso et
al., 2007). Our data are relevant in several
respects. First, our findings are consistent
with the hypothesis that hallucinogens ex-
ert their effects at cortical pyramidal neu-
ron apical dendrites. Apical dendritic ac-
tivity has been implicated as forming the
neural basis for cognition and conscious-
ness (LaBerge, 2006; Laberge and Kasev-
ich, 2007), and it is thought that cortico-
cortical connections, which are primarily
composed of synaptic contacts at apical
dendrites (Spratling, 2002), are important
in generating and shaping the neural activ-
ity that underlies consciousness (Tononi
and Edelman, 1998). Furthermore, the
primary neuro-anatomical site of expres-
sion of 5-HT2A receptors is the apical den-
drites of cortical pyramidal neurons, par-
ticularly in layer V pyramidal neurons
(Willins et al., 1997; Jakab and Goldman-
Rakic, 1998). Finally, a wide range of evi-
dence supports altered glutamatergic sig-
naling in neocortex as playing a key role in
mediating the effects of hallucinogens on
consciousness (Aghajanian and Marek,
Figure 6. Deletion of PSD-95 attenuates 5-HT2C receptor-mediated induction of c-fos.A, 5-HT2C and c-fos double-label immu-
nochemistry in the hippocampus of PSD-95wildtype and PSD-95 nullmice after MK-212 treatment (N 3 littermate pairs). Repre-
sentative images of CA1 and CA2 are shown. There are fewer c-fos-positive cells in the PSD-95 null mice treated with MK-212 in
both CA1 and CA2.B, Highermagnification image of CA1 to examine colocalization of 5-HT2C receptors and c-fos. 5-HT2C receptor
colocalizes with c-fos, suggesting that 5-HT2C is inducing this IEG directly, rather than indirectly in surrounding neurons. C,
Analysis of c-fos induction was performed by counting the number of c-fos-positive cells in CA1, CA2, CA3, and DG. Data are
presented as the mean number of c-fos-positive cells the SEM. There is a significant reduction in c-fos-positive cells in the
absence of PSD-95 in all four regions that were measured. c-fos counts were performed separately in the hippocampus of each
hemisphere (2 values for each section analyzed). Every seventh section was analyzed, for a total of six sections per animal. *p
0.05, **p 0.01, ***p 0.001; one-tailed unpaired t test.
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1999). Importantly, our studies demonstrate that the overall ex-
pression and apical dendritic targeting of 5-HT2A receptors to
postsynaptic densities is significantly impaired in cortical neu-
rons prepared from PSD-95null mice. Also, DOI is unable to in-
duce p-ERK1/2 and p-GSK3 in PSD-
95null mice. Not surprisingly, DOI-
induced head-twitch behavior, the
behavioral correlate of hallucinogen ac-
tion, is also reduced. Moreover, we found
that the reintroduction of PSD-95 into
PSD-95null neurons rescues both the defi-
cient expression and targeting phenotype.
Our data provide a mechanism
whereby5-HT2A receptors canbe targeted to
a cortical, postsynaptic site of action and
trafficked appropriately once they have ar-
rived. In fact, our studies have provided the
first candidate subcellular locus for halluci-
nogenaction, thePSD-95-scaffoldedmacro-
molecular signaling complexof cortical neu-
rons. Given the accumulating evidence that
hallucinogenic action involves alterations in
synaptic activity, ourdata further suggest the
possibility thathallucinogensmayexert their
actions via PSD-95-mediated interactions
with glutamatergic signaling complexes
downstream of 5-HT2A receptor activation.
Atypical antipsychotics are ineffective in
the absence of PSD-95
It has been known for some time that PCP,
a noncompetitive NMDA receptor antag-
onist, induces psychotic and “deficit”
states that are nearly indistinguishable
from the positive and negative symptoms
of schizophrenia (Jentsch and Roth, 1999;
Olney et al., 1999; Javitt, 2004). Further-
more, clozapine and other drugs with potent 5-HT2A inverse ag-
onist actions ameliorate PCP-induced PPI deficits (Carlsson et
al., 1999; Yamada et al., 1999; Geyer et al., 2001; Linn et al., 2003).
Figure 7. 5-HT2A-mediated head-twitch behavior is attenuated in PSD-95
nullmice. A, 5-HT2A-mediated head-twitch response after intraperitoneal injection of 5mg/kg DOI (N 11 littermate
pairs) and 5-HT1A-mediated hypothermic response after intraperitoneal injection of 5 mg/kg 8-OH-DPAT (N 12 littermate pairs). There is a significant decrease in DOI-induced head-twitch in
PSD-95 nullmice, in contrast with themagnitude of the decrease in core body temperature induced by 8-OH-DPAT, which is the same in both PSD-95wildtype and PSD-95 nullmice.B–D, Western blot
and associated quantification for p-ERK1/2, ERK1/2, p-GSK3, and GSK3 15min after intraperitoneal injection of vehicle or DOI (N 4–5 littermate pairs). DOI induces pERK1/2 and pGSK3 in
wild-type, but not null,mice. For quantification, p-ERK1/2 and p-GSK3were normalized to ERK1/2 andGSK3, respectively. Data are given asmeans the SEM; *p 0.05, **p 0.01, ***p
0.001; one-tailed unpaired t test.
Figure8. The antipsychotic-like efficacy of atypical antipsychotics is lost inPSD-95 nullmice. At the twoprepulses shown, 4 and
12 dB, PCP significantly disrupted PPI in PSD-95wildtype and PSD-95 null mice. In PSD-95wildtype mice, clozapine pretreatment
normalized the disruption of PPI by PCP at both 4 and12dB (N 6 littermate pairs). In contrast, inPSD-95 nullmice, clozapine had
no antipsychotic-like effect. B, PPI after treatment with clozapine alone (N 6 littermate pairs). Clozapine (0.5 mg/kg) had no
effect on PPI compared with vehicle. C, PPI in PSD-95wildtype and PSD-95 null mice after injection of vehicle, 6.0 mg/kg PCP, 0.5
mg/kgM100907plus 6.0mg/kgPCP, or 1.0mg/kg SR46349Bplus 6.0mg/kgPCP. PCP significantly disruptedPPI inPSD-95wildtype
and PSD-95 null mice at 4 and 8 dB (N  12). In PSD-95wildtype mice, M100907 or SR46349B pretreatment normalized the
disruption of PPI by PCP at 4 and 8 dB, whereas in PSD-95 null mice, they had no antipsychotic-like effect. D, Locomotion after
vehicle, 6.0mg/kg PCP, and 1.0mg/kg SR46349B plus 6.0mg/kg PCP in PSD-95wildtype and PSD-95 nullmice (N 12). SR46349B
normalizes PCP-induced hyperlocomotion in PSD-95wildtype mice only. Data are given as means the SEM; *p 0.05, **p
0.01, ***p 0.001; two-way repeated-measures ANOVA followed by Bonferroni post-tests.
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Finally, genetic deletion of PSD-95 or deletion of one of the PDZ
domains results in abnormalities in LTP, a phenotype related to
glutamatergic dysfunction (Migaud et al., 1998; Yao et al., 2004).
Together with our data, the evidence suggest that one of the key
subcellular locations at which the functional interplay between
5-HT2A receptors and glutamatergic signaling takes place is the
PSD-95-scaffolded postsynaptic density.
Since, in the absence of PSD-95, glutamatergic signaling is
abnormal, and 5-HT2A receptors are mistargeted and mistraf-
ficked, we predicted that theremay be abnormalities in the ability
of clozapine and selective 5-HT2A antagonists to alleviate PCP-
induced psychotic-like behaviors in mice. We found that cloza-
pine, M100907, or SR46349B treatment, which reduced PCP-
induced deficits of PPI in PSD-95wildtype mice, was completely
ineffective in PSD-95null mice. The dramatically impaired
antipsychotic-like action of the aforementioned atypical antipsy-
chotics in the PSD-95null mice is likely attributable to the com-
bined abnormalities in 5-HT2A and 5-HT2C receptor function—
both of which have long been thought to be essential for their
unique benefits (Roth et al., 2004a). Our studies clearly implicate
the 5-HT2A dysfunction that results in the absence of PSD-95 as
being responsible for the lack of atypical antipsychotic efficacy in
PSD-95null mice.
Conclusions
In this study, we demonstrate that PSD-95, in addition to its well
known role in scaffolding glutamatergic signaling complexes and
facilitating neuronal plasticity, potently regulates neuronal
metabotropic serotonin receptor targeting, trafficking, and sig-
naling in vivo. Furthermore, we show that the absence of PSD-95
results in abnormal downstream signaling for both 5-HT2A re-
ceptors and 5-HT2C receptors, both of which are important ther-
apeutic targets for a number of psychiatric diseases.We also show
that the 5-HT2A dysfunction has profound consequences with
regards to the treatment of psychotic-like states in relevant ani-
mal models. Our findings demonstrate an unexpectedly pro-
found role for PSD-95 in regulating 5-HT2A and 5-HT2C receptor
function and the behavioral responses to drugs acting at these
receptors. These results imply that PSD-95may serve as a scaffold
to integrate information between ionotropic and metabotropic
neurotransmission at postsynaptic densities.
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